280 related articles for article (PubMed ID: 11892905)
1. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Lavrenkov K; Man S; Mermershtain W; Cohen Y
J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
[TBL] [Abstract][Full Text] [Related]
6. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
9. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Hofheinz R; Hartung G; Samel S; Emig M; Pilz L; Willeke F; Hochhaus A; Hehlmann R; Queisser W
Anticancer Drugs; 2002 Nov; 13(10):999-1004. PubMed ID: 12439333
[TBL] [Abstract][Full Text] [Related]
10. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Van Cutsem E; Blijham GH
Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
[TBL] [Abstract][Full Text] [Related]
11. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Kamnerdsupaphon P; Lorvidhaya V; Chitapanarux I; Tonusin A; Sukthomya V
J Med Assoc Thai; 2007 Oct; 90(10):2121-7. PubMed ID: 18041432
[TBL] [Abstract][Full Text] [Related]
14. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
15. Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
Benavides M; García-Alfonso P; Cobo M; Muñoz-Martín A; Gil-Calle S; Carabantes F; Villar E; Graupera J; Balcells M; Pérez-Manga G
Med Oncol; 2004; 21(3):255-62. PubMed ID: 15456953
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Van Cutsem E; Cunningham D; Ten Bokkel Huinink WW; Punt CJ; Alexopoulos CG; Dirix L; Symann M; Blijham GH; Cholet P; Fillet G; Van Groeningen C; Vannetzel JM; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
Eur J Cancer; 1999 Jan; 35(1):54-9. PubMed ID: 10211088
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Pitot HC; Wender DB; O'Connell MJ; Schroeder G; Goldberg RM; Rubin J; Mailliard JA; Knost JA; Ghosh C; Kirschling RJ; Levitt R; Windschitl HE
J Clin Oncol; 1997 Aug; 15(8):2910-9. PubMed ID: 9256135
[TBL] [Abstract][Full Text] [Related]
18. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
[TBL] [Abstract][Full Text] [Related]
19. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
Rougier P; Bugat R
Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Garufi C; Dogliotti L; D'Attino RM; Tampellini M; Aschelter AM; Pugliese P; Perrone M; Nisticó C; Comis S; Terzoli E
Cancer; 2001 Feb; 91(4):712-20. PubMed ID: 11241238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]